Government Investigation Preparedness for Pharma

Developing the playbook for new domestic and international challenges

Tuesday, January 23, 2007

About

In the publication from the Government Investigation Preparedness for Pharma conference, have access to insightful and informative presentations to help you navigate your way through the variables and intricacies of a government investigation in the drug industry with firsthand accounts by attorneys who have been through it before.

Stop being a target for government investigations!

Learn new strategies to meet the government head on.

Despite companies' best efforts to comply with government regulations, the pharmaceutical industry continues to be the focus of government investigations. Pharma companies routinely pay hundreds of millions of dollars to settle government claims, and the consequences can be devastating.

Changes in the way the government conducts investigations may be underway

While it doesn't seem that the targeting of pharmaceutical companies will end any time soon, the tide may be turning. The government suffered a setback with the recent KPMG decision and is now on the defensive. A new game in the world of compliance and government investigations is evolving and it's time for pharma companies to seize this opportunity.

Reassess and refine your client's investigations playbook

Contents & Contributors

About

In the publication from the Government Investigation Preparedness for Pharma conference, have access to insightful and informative presentations to help you navigate your way through the variables and intricacies of a government investigation in the drug industry with firsthand accounts by attorneys who have been through it before.

Stop being a target for government investigations!

Learn new strategies to meet the government head on.

Despite companies' best efforts to comply with government regulations, the pharmaceutical industry continues to be the focus of government investigations. Pharma companies routinely pay hundreds of millions of dollars to settle government claims, and the consequences can be devastating.

Changes in the way the government conducts investigations may be underway

While it doesn't seem that the targeting of pharmaceutical companies will end any time soon, the tide may be turning. The government suffered a setback with the recent KPMG decision and is now on the defensive. A new game in the world of compliance and government investigations is evolving and it's time for pharma companies to seize this opportunity.

Reassess and refine your client's investigations playbook

Contents & Contributors


INDEMNIFYING EMPLOYEES: WHERE THE GOVERNMENT STANDS & WHERE THE CORPORATION SHOULD STAND
Lisa C. Dykstra, Morgan, Lewis & Bockius LLP (Philadelphia, PA)

FCPA AND INTERNATIONAL WHITE COLLAR CRIME BASICS THAT EVERY PHARMA COMPANY NEEDS TO KNOW
Eric A. Dubelier, Reed Smith LLP (Washington, DC)
Michael Kendall, McDermott Will & Emery LLP (Boston, MA)
Mark Lurie, Eisai Corporation of North America (Teaneck, NJ)

MANAGING FCPA INVESTIGATIONS AND PROSECUTION RISKS
Richard N. Dean, Baker & McKenzie LLP (Washington, DC)

GLOBAL ENFORCEMENT AFFECTING PHARMACEUTICAL MARKETING: CURRENT TRENDS AND ASSESSMENT
Stephen J. Immelt, Hogan & Hartson LLP (Baltimore, MD)

SELECT FEATURES OF INTERNATIONAL IN-HOUSE COUNSEL ATTORNEY-CLIENT PRIVILEGE LAWS
Michael S. Kim, Kobre & Kim LLP (New York)

NOTEWORTHY RECENT FOREIGN INVESTIGATIONS CORRESPONDING LOCAL INTEGRITY LAWS
Michael S. Kim, Kobre & Kim LLP (New York)

IMPLEMENTING ANTI-BRIBERY COMPLIANCE PROGRAMS: KEYS TO MEETING NEW FCPA COMPLIANCE STANDARDS
Gary Giampetruzzi, Pfizer Inc. (New York)

ENSURING FCPA COMPLIANCE FOR FOREIGN OPERATIONS
R. Christopher Cook, Jones Day (Washington, DC)

FCPA COMPLIANCE PRACTICE TIPS
Christopher Zalesky, Johnson & Johnson (New Brunswick, NJ)

AFTERMATH OF AN ENFORCEMENT ACTION: APPOINTING & WORKING WITH SPECIAL COMPLIANCE MONITORS
Frederic R. Miller, PricewaterhouseCoopers (Washington, DC)
Michael L. Burton, Arent Fox PLLC (Washington, DC)

DETERMINING WHEN IF EVER THE ATTORNEY/CLIENT PRIVILEGE SHOULD BE WAIVED
Thomas M. Gallagher, Pepper Hamilton LLP (Philadelphia, PA)

ASSESSING YOUR OPTIONS ONCE A GOVERNMENT INVESTIGATION IS INITIATED IT'S NOT NECESSARILY TIME TO THROW IN THE TOWEL!
Arthur E. Brown, Kaye Scholer LLP (New York)
Katherine A. Lauer, Latham & Watkins LLP (San Diego, CA)
Gregory J. Wallance, Kaye Scholer LLP, (New York)

BULLETPROOFING YOUR SALES AND MARKETING PRACTICES FROM GOVERNMENT SCRUTINY
Ralph F. Hall, Baker & Daniels LLP (Indianapolis, IN)
Christopher Myers, Holland & Knight LLP (McLean, VA)

WEIGHING THE PROS AND CONS OF VOLUNTARY DISCLOSURES
Kathleen McDermott, Blank Rome LLP (Washington, DC)



DOCUMENT TYPES: PRESENTATIONS AVAILABLE: 0